13F Holdings
中文EN

SERA SERA PROGNOSTICS, INC.

Services-Medical Laboratories · Nasdaq · SEC CIK 1534969 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.1%
TTM net income YoY-2.6%
TTM EPS YoY11.8%
Revenue 3-yr CAGR-33.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-38,755.2%
Net margin-34,866.7%
FCF margin-30,199.0%
EBITDA margin-37,922.9%

Returns

ROE-49.7%
ROA-35.6%
ROIC (approx.)-46.5%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets34.4%
Debt / equity0.00x
Current ratio1.88x
Interest coverage-5,315.00x

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue508.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$81,000$77,000$306,000$268,000$82,000
Cost of revenue$164,000$82,000$210,000——
Gross profit-$83,000-$5,000$96,000——
R&D expense$13.17M$14.73M$15.22M$14.24M$11.02M
SG&A expense$16.70M$16.13M$16.34M$16.78M$14.09M
Operating income-$36.50M-$36.63M-$39.82M-$45.65M-$35.40M
Interest expense$9,000$28,000$55,000——
Pretax income-$31.93M-$32.90M———
Income tax$0$0$0$0$0
Net income-$31.93M-$32.90M-$36.24M-$44.19M-$35.01M
EBITDA-$35.56M-$35.80M-$38.92M-$44.90M-$34.74M
EPS (basic)-0.67-0.99-1.16-1.43-2.33
EPS (diluted)-0.67-0.99-1.16-1.43-2.33
Weighted avg. shares (diluted)47.66M33.16M31.20M30.94M15.00M
Balance sheet
Cash & equivalents$3.94M$4.04M$3.88M$29.88M$58.93M
Short-term investments$35.26M$42.19M$45.20M$52.83M$46.18M
Receivables$12,000$34,000$160,000$113,000$27,000
Current assets$40.77M$47.60M$61.34M$90.12M$110.25M
PP&E, net$1.15M$1.24M$2.00M$3.06M$1.77M
Intangibles$910,000$1.03M$0——
Total assets$101.93M$72.58M$95.44M$116.33M$147.03M
Current liabilities$24.19M$24.77M$24.44M$15.54M$8.41M
Total liabilities$26.52M$24.77M$25.28M$17.39M$8.46M
Shareholders' equity$75.41M$47.80M$70.16M$98.94M$138.56M
Cash flow statement
Operating cash flow-$25.62M-$14.19M-$27.19M-$34.61M-$31.64M
Capital expenditure$726,000$56,000$128,000$791,000$1.30M
Free cash flow-$26.35M-$14.24M-$27.32M-$35.40M-$32.94M
Investing cash flow-$28.50M$11.74M$438,000$5.55M-$82.56M
Financing cash flow$54.03M$2.61M$752,000$5,000$159.59M
Depreciation & amortization$940,000$833,000$900,000$756,000$659,000
Stock-based compensation$5.11M$7.01M$5.27M$5.05M$3.13M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.